Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 151

    Novartis division Alcon spinoff ousts Baer from Swiss benchmark SMI

    Novartis division Alcon spinoff ousts Baer from Swiss benchmark SMI

    Medical Dialogues Bureau5 April 2019 9:00 AM IST
    Novartis has estimated Alcon's value at around 25 billion Swiss francs ($25 billion), while some analysts predict an initial market capitalisation of...
    Government notifies Organ Preservative Solutions as DRUGS with immediate effect

    Government notifies Organ Preservative Solutions as DRUGS with immediate effect

    Meghna A Singhania4 April 2019 11:13 AM IST
    New Delhi: In a move to monitor and assure quality Organ Preservative Solutions (OPS) the Government has specified OPS as "Drugs."Through a recent...
    Emcure launches generic Eribulin at 40 percent lower price in India

    Emcure launches generic Eribulin at 40 percent lower price in India

    Farhat Nasim4 April 2019 9:30 AM IST
    Emcure Pharmaceuticals will manufacture Eribulin at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent...
    Novartis division resubmits USFDA application for biosimilar Pegfilgrastim

    Novartis division resubmits USFDA application for biosimilar Pegfilgrastim

    Farhat Nasim4 April 2019 9:15 AM IST
    New Delhi: Novartis division, Sandoz, recently announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar...
    Roche extends Spark Therapeutics offer worth 4.3 billion USD

    Roche extends Spark Therapeutics' offer worth 4.3 billion USD

    Garima4 April 2019 9:14 AM IST
    Roche needs to get at least a majority of outstanding Spark stock for the offer to go through.ZURICH: Roche Holding has extended until May 2 its $4.3...
    Family behind OxyContin calls opioid suit false, misleading

    Family behind OxyContin calls opioid suit false, misleading

    Medical Dialogues Bureau4 April 2019 9:04 AM IST
    BOSTON: Massachusetts authorities created a false picture of the Sackler family's role in promoting OxyContin, the Sacklers said Tuesday in their...
    Cigna caps insulin prices at $25 for 30 days

    Cigna caps insulin prices at $25 for 30 days

    Medical Dialogues Bureau4 April 2019 9:00 AM IST
    Cigna, which bought pharmacy benefits manager Express Scripts last year, said it was partnering with insulin manufacturers to lower copayments to $25...
    NPPA revises ceiling price of 847 formulations including Metformin, Atrovastatin; Details

    NPPA revises ceiling price of 847 formulations including Metformin, Atrovastatin; Details

    Meghna A Singhania3 April 2019 6:08 PM IST
    New Delhi: Through a recent notification, National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling prices of 847 formulations under the...
    CDSCO calls for crackdown on Buclizine sales; Mankind Pharma taken to court: Report

    CDSCO calls for crackdown on Buclizine sales; Mankind Pharma taken to court: Report

    Meghna A Singhania3 April 2019 11:45 AM IST
    Those found manufacturing, selling or distributing buclizine on or after December 13 without adhering to the orders given by CDSCO, will be liable for...
    Dr Reddys arm sells US rights for Sernivo, Promises, Trianex to Encore Dermatology

    Dr Reddy's arm sells US rights for Sernivo, Promises, Trianex to Encore Dermatology

    Farhat Nasim3 April 2019 9:30 AM IST
    Dr Reddy's co-chairman and CEO G V Prasad said the announcement is in line with its renewed strategy to enable us to achieve self-sustainability and...
    USFDA issues warning letter to Rajasthan based homeopathic firm and 3 others

    USFDA issues warning letter to Rajasthan based homeopathic firm and 3 others

    Farhat Nasim3 April 2019 9:25 AM IST
    New Delhi: The U.S. Food and Drug Administration (USFDA) recently posted warning letters to four companies producing homoeopathic drug products for...
    Pfizer participates in SpringWorks Therapeutics USD125 million Series B financing

    Pfizer participates in SpringWorks Therapeutics' USD125 million Series B financing

    Garima3 April 2019 9:15 AM IST
    All of the SpringWorks Therapeutics' existing investors, OrbiMed, Bain Capital, Pfizer, via Pfizer Ventures, and LifeArc have also participated in the...
    PrevNext

    Popular Stories

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Regulation of OTC drugs : CDSCO to soon amend Schedule K of Drugs and Cosmetics Act

    Regulation of OTC drugs : CDSCO to soon amend Schedule K of Drugs and Cosmetics Act

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Why Family Health Insurance Plan needs a Timely Re-Evaluation?

    Why Family Health Insurance Plan needs a Timely Re-Evaluation?

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok